Taysha Gene Therapies Quarterly Income Statements Chart
Quarterly
|
Annual
Taysha Gene Therapies Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenue | 1,986,000 | 2,302,000 | 2,022,000 | 1,788,000 | 1,112,000 | 3,411,000 | 3,604,000 | 4,746,000 | 2,395,000 | 4,706,000 | ||||||||||
| yoy | 78.60% | -32.51% | -43.90% | -62.33% | -53.57% | -27.52% | ||||||||||||||
| qoq | -13.73% | 13.85% | 13.09% | 60.79% | -67.40% | -5.36% | -24.06% | 98.16% | -49.11% | |||||||||||
| operating expenses: | ||||||||||||||||||||
| research and development | 20,141,000 | 15,565,000 | 15,325,000 | 14,946,000 | 15,073,000 | 20,657,000 | 12,682,000 | 11,791,000 | 19,791,000 | 12,514,000 | 13,861,000 | 16,391,000 | 23,118,000 | 37,799,000 | 37,918,000 | 39,528,000 | 30,643,000 | 23,854,000 | 12,260,000 | 11,057,000 |
| general and administrative | 8,598,000 | 8,158,000 | 6,629,000 | 7,902,000 | 7,338,000 | 7,084,000 | 6,719,000 | 8,589,000 | 5,988,000 | 8,751,000 | 7,341,000 | 8,683,000 | 9,867,000 | 11,469,000 | 11,806,000 | 11,153,000 | 10,129,000 | 8,236,000 | 6,107,000 | 3,984,000 |
| total operating expenses | 28,739,000 | 23,723,000 | 21,954,000 | 27,686,000 | 22,411,000 | 27,741,000 | 19,850,000 | 20,996,000 | 25,779,000 | 21,265,000 | 57,622,000 | 25,074,000 | 32,985,000 | 49,268,000 | 49,724,000 | 50,681,000 | 40,772,000 | 32,090,000 | 18,367,000 | 15,041,000 |
| income from operations | -26,753,000 | -21,421,000 | -19,932,000 | -25,898,000 | -21,299,000 | -24,330,000 | -16,246,000 | -16,250,000 | -23,384,000 | -16,559,000 | -55,120,000 | -25,074,000 | -32,985,000 | -49,268,000 | -49,724,000 | -50,681,000 | -40,772,000 | -32,090,000 | -18,367,000 | -15,041,000 |
| yoy | 25.61% | -11.96% | 22.69% | 59.37% | -8.92% | 46.93% | -70.53% | -35.19% | -29.11% | -66.39% | 10.85% | -50.53% | -19.10% | 53.53% | 170.72% | 236.95% | ||||
| qoq | 24.89% | 7.47% | -23.04% | 21.59% | -12.46% | 49.76% | -0.02% | -30.51% | 41.22% | -69.96% | 119.83% | -23.98% | -33.05% | -0.92% | -1.89% | 24.30% | 27.06% | 74.72% | 22.11% | |
| operating margin % | -1347.08% | -930.54% | -985.76% | -1448.43% | -1915.38% | -713.28% | -450.78% | -342.39% | -976.37% | -351.87% | ||||||||||
| other income: | ||||||||||||||||||||
| change in fair value of warrant liability | -273,000 | 102,000 | 83,000 | 75,000 | 195,000 | -337,000 | 65,738,000 | -100,456,000 | ||||||||||||
| change in fair value of term loan | -1,461,000 | -1,530,000 | -548,000 | -1,703,000 | -1,279,000 | -1,053,000 | ||||||||||||||
| interest income | 1,859,000 | 1,326,000 | 1,700,000 | 2,107,000 | 1,440,000 | 1,693,000 | 1,921,000 | 1,109,000 | 223,000 | 319,000 | 199,000 | 9,000 | 27,000 | 14,000 | 29,000 | 37,000 | 40,000 | 66,000 | ||
| interest expense | -17,000 | -19,000 | -22,000 | -24,000 | -27,000 | -29,000 | -713,000 | -1,471,000 | -1,440,000 | -1,374,000 | -796,000 | -1,241,000 | -912,000 | -849,000 | -691,000 | -543,000 | -194,000 | -1,000 | ||
| other income | -237,000 | 13,000 | -66,000 | -81,000 | 42,000 | -5,000 | -23,000 | -19,000 | 3,000 | -8,000 | -6,000 | -1,000 | -3,000 | -8,000 | ||||||
| total other income | -129,000 | -108,000 | 1,147,000 | 374,000 | 371,000 | 269,000 | 63,987,000 | -100,837,000 | -1,214,000 | -1,063,000 | -603,000 | -1,233,000 | -888,000 | -843,000 | -662,000 | -506,000 | -154,000 | 66,000 | 49,000 | -1,000 |
| net income | -26,882,000 | -21,529,000 | -18,785,000 | -25,524,000 | -20,928,000 | -24,061,000 | 47,741,000 | -117,087,000 | -24,598,000 | -17,622,000 | -55,723,000 | -26,307,000 | -33,873,000 | -50,111,000 | -50,386,000 | -51,187,000 | -40,926,000 | -32,024,000 | -18,318,000 | -15,042,000 |
| yoy | 28.45% | -10.52% | -139.35% | -78.20% | -14.92% | 36.54% | -185.68% | 345.08% | -27.38% | -64.83% | 10.59% | -48.61% | -17.23% | 56.48% | 175.06% | 240.29% | ||||
| qoq | 24.86% | 14.61% | -26.40% | 21.96% | -13.02% | -150.40% | -140.77% | 376.00% | 39.59% | -68.38% | 111.82% | -22.34% | -32.40% | -0.55% | -1.56% | 25.07% | 27.80% | 74.82% | 21.78% | |
| net income margin % | -1353.58% | -935.23% | -929.03% | -1427.52% | -1882.01% | -705.39% | 1324.67% | -2467.07% | -1027.06% | -374.46% | ||||||||||
| net income per common share, basic and diluted | -90 | -80 | -70 | -100 | -90 | -100 | 920 | -930 | -380 | -280 | -1,010 | -640 | -840 | -1,310 | -1,330 | -1,350 | -1,090 | -870 | 330 | -1,280 |
| weighted-average common shares outstanding, basic and diluted | 297,988,978,000 | 269,306,331,000 | 250,134,421,000 | 267,824,045,000 | 232,821,553,000 | 231,249,344,000 | 116,121,482,000 | 125,700,799,000 | 64,244,531,000 | 63,260,905,000 | 43,952,015,000 | 40,937,808,000 | 40,142,403,000 | 38,174,717,000 | 37,650,566,000 | 38,003,954,000 | 37,479,164,000 | 36,992,377,000 | 17,665,683,000 | 11,733,170,000 |
| impairment of long-lived assets | 4,838,000 | 449,000 | 616,000 | |||||||||||||||||
| change in fair value of preferred stock tranche liability |
We provide you with 20 years income statements for Taysha Gene Therapies stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Taysha Gene Therapies stock. Explore the full financial landscape of Taysha Gene Therapies stock with our expertly curated income statements.
The information provided in this report about Taysha Gene Therapies stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.